Ranitidine 50mg/2ml injection is anticipated to be unavailable from the end of May 2020 until further notice.
Ranitidine film-coated tablets, effervescent tablets and oral solution continue to remain unavailable with no date for resupply. This is due to on-going regulatory investigations into the presence of the contaminant, N-nitrosodimethylamine (NDMA).
Clinical advice on alternatives of ranitidine preparations for adults and children has been shared in the previous supply disruption alert
View the update.